MY197202A - A liquid formulation of anti-tnf alpha antibody - Google Patents

A liquid formulation of anti-tnf alpha antibody

Info

Publication number
MY197202A
MY197202A MYPI2019005331A MYPI2019005331A MY197202A MY 197202 A MY197202 A MY 197202A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY 197202 A MY197202 A MY 197202A
Authority
MY
Malaysia
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
MYPI2019005331A
Other languages
English (en)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY197202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MY197202A publication Critical patent/MY197202A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MYPI2019005331A 2017-03-16 2018-03-16 A liquid formulation of anti-tnf alpha antibody MY197202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Publications (1)

Publication Number Publication Date
MY197202A true MY197202A (en) 2023-05-31

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005331A MY197202A (en) 2017-03-16 2018-03-16 A liquid formulation of anti-tnf alpha antibody

Country Status (15)

Country Link
JP (2) JP7109849B2 (fr)
KR (2) KR20180106974A (fr)
CN (1) CN110621303A (fr)
AU (1) AU2018236651B2 (fr)
BR (1) BR112019019162A2 (fr)
CO (1) CO2019010860A2 (fr)
MA (1) MA46988A1 (fr)
MX (1) MX2019010895A (fr)
MY (1) MY197202A (fr)
NZ (1) NZ757965A (fr)
PH (1) PH12019502075A1 (fr)
RU (1) RU2756619C2 (fr)
UA (1) UA123847C2 (fr)
WO (1) WO2018169348A1 (fr)
ZA (1) ZA201906696B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
CN103458926B (zh) * 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SG10201609982PA (en) * 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
EP2948473A1 (fr) * 2013-01-24 2015-12-02 GlaxoSmithKline Intellectual Property Development Limited Protéines de liaison à l'antigène tnf-alpha
AR095496A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US20150274819A1 (en) * 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (fr) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Composition pharmaceutique liquide d'adalimumab
EP3050557A1 (fr) * 2014-05-23 2016-08-03 Ares Trading S.A. Composition pharmaceutique liquide
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Also Published As

Publication number Publication date
JP2020510079A (ja) 2020-04-02
JP2022097600A (ja) 2022-06-30
RU2019130728A3 (fr) 2021-04-16
KR20200096472A (ko) 2020-08-12
JP7109849B2 (ja) 2022-08-01
WO2018169348A1 (fr) 2018-09-20
CO2019010860A2 (es) 2020-01-17
AU2018236651A1 (en) 2019-10-31
UA123847C2 (uk) 2021-06-09
KR20180106974A (ko) 2018-10-01
PH12019502075A1 (en) 2020-09-14
MA46988A1 (fr) 2020-06-30
RU2756619C2 (ru) 2021-10-04
AU2018236651B2 (en) 2020-12-10
NZ757965A (en) 2022-07-01
MX2019010895A (es) 2019-11-05
KR102342292B1 (ko) 2021-12-24
ZA201906696B (en) 2020-08-26
BR112019019162A2 (pt) 2020-04-14
RU2019130728A (ru) 2021-04-16
CN110621303A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MY198059A (en) Anti-ox40 antibodies and their uses
EP4257613A3 (fr) Anticorps inhibiteurs de points de contrôle bispécifiques
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
EP4335874A3 (fr) Anticorps anti-hla-g et leur utilisation
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY191581A (en) Anti-pd-1 antibodies
WO2016061389A3 (fr) Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
MX2023006416A (es) Anticuerpos, usos y metodos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
PH12019502694A1 (en) Anti-trkb antibodies
MY195448A (en) New Anti-Sirpa Antibodies and Their Therapeutic Applications
MX2017016258A (es) Antigenos de leucemia mieloide aguda (aml) y usos de los mismos.